Press

Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

Jun 7 • 4 min read

VANCOUVER, BC, June 7, 2024 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a leader in mental health care specializing in innovative and evidence-based treatments, comments on the results of June 4, 2024 meeting of the U.S. Food and Drug Administration’s (“FDA”) Psychopharmacologic Drugs Advisory Committee (“PDAC”). The independent committee reviewed Lykos Therapeutics’ new drug…

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Jun 7 • 3 min read

SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company’s SP-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain. An ongoing…

Red Light Holland Announces Completion of Full Psilocybin Extraction Report with PharmAla

Jun 7 • 2 min read

Toronto, Ontario–(Newsfile Corp. – June 7, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland”), a company engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles to the legal,…

Pharmala Biotech: CEO Letter To Shareholders

Jun 7 • 5 min read

Over the past 48 hours, a large number of shareholders have reached out to me for my thoughts on the recent FDA Advisory Committee Meeting convened to discuss the Lykos Therapeutics application for New Drug Approval for Midomafetamine (MDMA). As most of you know by now, the committee overwhelmingly voted that there was not enough…

Psych Capital Changes Name To Shortwave Life Sciences

Jun 7 • 1 min read

Shortwave Life Sciences PLC – London-based drug development for mental health – Changes name from Psych Capital following the acquisition of Shortwave Pharma Inc last year. Says the new name reflects its focus on mental health, particularly eating disorders. This includes psychedelics-based therapies. “Eating disorders, including anorexia nervosa, bulimia nervosa, and binge-eating disorder, represent a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435